# Cyrano Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cyrano-therapeutics

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.cyranotherapeutics.com
- Total disclosed funding: $19M
- Latest round: Series B (Dec 21, 2023)
- Investors on record: 3

## About

Based in Washington, US, and founded in 2014, Cyrano Therapeutics, Inc., operates as a pharmaceutical company that develops therapeutic solutions for olfactory dysfunction, a condition that limits the ability to taste and smell. In November 2020, Cyrano Therapeutics, Inc. raised USD 4.08 million in Series A funding, co-led by investors Lumira Ventures and Remiges Ventures. As of 2022, the company is led by its CEO and President, Rick Geoffrion.

The company offers regenerative medicine for loss of smell and flavor function. The company has created a proprietary intranasal product to help patients with chronic loss of taste and smell regain function. The company is working to determine an optimal dose and validate the therapy in a double-blind, randomized setting.

## Funding rounds

- Series B, Dec 21, 2023, $15M — Remiges Ventures, DeepWork Capital, Lumira Ventures
- Series A, Nov 4, 2020, $4.1M — Remiges Ventures, Lumira Ventures

## Investors

- Remiges Ventures (https://capitalatlas.ai/funds/remiges-ventures) — Series A, Series B
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A, Series B
- DeepWork Capital (https://capitalatlas.ai/funds/deepwork-capital) — Series B